{"gene":"GALC","run_date":"2026-06-10T01:55:20","timeline":{"discoveries":[{"year":2018,"finding":"GALC and the saposin SapA form a heterotetramer complex that creates an open channel connecting the GALC active site to the SapA hydrophobic cavity, revealing the mechanism by which a soluble lysosomal hydrolase cleaves the polar glycosyl headgroups of glycosphingolipids (galactocerebroside) from their hydrophobic ceramide tails. This structure also defines how specificity of saposin binding to hydrolases is encoded.","method":"Cryo-EM/crystal structure of GALC-SapA complex with functional validation","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic structure of the complex with functional mechanistic interpretation, multiple orthogonal structural methods in a single rigorous study","pmids":["29323104"],"is_preprint":false},{"year":1995,"finding":"GALC catalyzes the lysosomal hydrolysis of galactolipids including galactosylceramide (galactocerebroside) and galactosylsphingosine (psychosine). The gene spans ~60 kb and consists of 17 exons, establishing the genomic organization relevant to understanding enzyme structure-function.","method":"Gene cloning, cDNA sequencing, genomic library analysis, enzyme activity assay","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical characterization of enzymatic activity and gene structure, replicated across multiple studies","pmids":["7601472"],"is_preprint":false},{"year":1996,"finding":"GALC is secreted into the media by transduced fibroblasts and taken up by untransduced neighboring cells. Mannose-6-phosphate receptor-mediated uptake is only partially responsible for the efficient transfer of GALC to neighboring cells (cross-correction). The transferred GALC is localized to lysosomes and is functionally active, as demonstrated by normal metabolism of [14C]stearic acid-labeled galactosylceramide.","method":"Retroviral transduction, GALC activity assay, [14C]-substrate metabolic labeling, lysosomal localization assay","journal":"Biochemical and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays in a single lab demonstrating lysosomal localization and partial M6P-receptor-dependent cross-correction","pmids":["8812733"],"is_preprint":false},{"year":2020,"finding":"Cross-correction of GALC does not occur efficiently in vivo in the peripheral nervous system. Galc-deficient Schwann cells autonomously produce psychosine. Galc-deficient macrophages cannot degrade myelin and are transformed into globoid cells upon exposure to galactosylceramide, producing a more severe GLD phenotype. Hematopoietic stem cell transplantation reduces globoid cells in patient nerves via phagocytic activity of healthy macrophages rather than cross-correction.","method":"Novel GLD mouse model, macrophage-specific GALC deletion, psychosine measurement, histopathology, hematopoietic stem cell transplantation in patients","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models and orthogonal methods (cell biology, mouse models, patient tissue) establishing macrophage-autonomous mechanism","pmids":["32375064"],"is_preprint":false},{"year":2016,"finding":"Infantile-onset GALC mutants show reduced trafficking to lysosomes and reduced proteolytic processing compared to later-onset mutants when measured in the lysosomal fraction, even when total cell lysate activity appears similar. Cis-polymorphisms in GALC also affect lysosomal trafficking and processing, explaining imperfect genotype-phenotype correlations.","method":"Subcellular fractionation, GALC activity assay in lysosomal vs. whole-cell fractions, site-directed mutagenesis, cell transfection","journal":"The Journal of Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct lysosomal fractionation with enzymatic quantification, multiple mutants and polymorphisms tested in parallel with functional consequences","pmids":["26865610"],"is_preprint":false},{"year":1996,"finding":"Expression studies in COS-1 cells demonstrated that the A to C transversion at cDNA position 473 (Y158S) is the disease-causing mutation in canine GLD, establishing this specific amino acid as critical for GALC enzymatic activity.","method":"COS-1 cell expression assay, site-directed mutagenesis, GALC activity measurement","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro expression assay with functional activity readout, single lab","pmids":["8661004"],"is_preprint":false},{"year":2006,"finding":"The twitcher mouse has a premature stop codon (W339X) in GALC that triggers nonsense-mediated mRNA decay (NMD), resulting in reduced GALC transcript levels proportional to the number of twitcher alleles. NMD inhibitors (anisomycin, emetine, puromycin) restored GALC transcript levels in twitcher-derived Schwann cells, confirming NMD as the mechanism by which no GALC protein is detected.","method":"RT-PCR/Northern blot for mRNA quantification, NMD inhibitor treatment, immunocytochemistry, Western blot","journal":"Neurobiology of Disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple NMD inhibitors tested, dose-allele relationship established, multiple orthogonal methods confirming NMD mechanism","pmids":["16759875"],"is_preprint":false},{"year":2006,"finding":"GALC expressed from lentiviral vectors accumulates in lysosomes of transduced neural cells and is also secreted to the extracellular medium. Conditioned GALC-containing medium corrects GALC deficiency in non-transduced twitcher glial cultures, confirming the secretory pathway of lysosomal enzyme delivery.","method":"Lentiviral transduction, immunofluorescence for lysosomal colocalization, GALC activity assay in conditioned medium and non-transduced cells","journal":"The journal of gene medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct lysosomal localization demonstrated by immunofluorescence and functional cross-correction in vitro, single lab","pmids":["16732552"],"is_preprint":false},{"year":1997,"finding":"The 5' flanking region of the human GALC gene is GC-rich with no CAAT or TATA sequences, contains Sp1 and YY1 binding sites, and a construct spanning nucleotides -176 to -24 has the strongest promoter activity. Inhibitory sequences exist immediately upstream of the promoter and in the first 234 nt of intron 1, which together with a suboptimal nucleotide at +4 explain the low levels of GALC protein in all cell types.","method":"Chloramphenicol acetyltransferase reporter gene assay with deletion constructs, promoter activity measurement","journal":"Biochemical and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay with multiple deletion constructs identifying active and inhibitory elements, single lab","pmids":["9441867"],"is_preprint":false},{"year":1997,"finding":"An intronic mutation IVS6+5G>A in the GALC gene causes exon 6 skipping. Transfection of a GALC mini-gene harboring this mutation proved that this specific intronic change is the cause of exon 6 skipping, resulting in loss of function.","method":"GALC mini-gene transfection assay, RT-PCR analysis of splicing","journal":"Genetic testing","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct mini-gene functional splicing assay demonstrating causality of the intronic mutation, single lab","pmids":["10464649"],"is_preprint":false},{"year":2007,"finding":"The novel GALC p.Gly41Ser substitution abolishes catalytic activity of galactocerebrosidase, as demonstrated by expression studies, and is responsible for late-onset Krabbe disease in a Sicilian founder population.","method":"Expression studies (cell transfection), GALC enzymatic activity assay","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — single lab, in vitro expression activity assay confirming loss of catalytic function","pmids":["17579360"],"is_preprint":false},{"year":2013,"finding":"The GALCtwi-5J missense mutation (E130K) causes loss of enzymatic activity despite normal levels of precursor protein, indicating the mutation disrupts catalytic function rather than protein production. The PNS is severely hypomyelinated and lacks large diameter axons (dysmyelination rather than demyelination), supporting a role for GALC enzymatic activity in primary myelination.","method":"Mouse model characterization, GALC activity assay, Western blot for precursor protein, neuropathology, electron microscopy","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockin mouse model with direct enzymatic and protein quantification, multiple orthogonal neuropathological methods","pmids":["23620143"],"is_preprint":false},{"year":2017,"finding":"Heterozygous GALC mutant mice (GALC+/-) have reduced myelin debris clearance and diminished remyelination after cuprizone-induced demyelination. The microglial phagocytic response and elevation of Trem2 (necessary for clearing damaged myelin) are markedly reduced in GALC+/- animals. These defects were corrected in vitro by NKH-477 treatment.","method":"Cuprizone demyelination model in GALC+/- mice, histological analysis of remyelination, microglial phagocytosis assay, Trem2 expression analysis, pharmacological rescue","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic mouse model with defined demyelinating insult, multiple outcome measures (remyelination, phagocytosis, Trem2), pharmacological rescue in vitro","pmids":["28575206"],"is_preprint":false},{"year":2015,"finding":"N-octyl-4-epi-β-valienamine (NOEV) acts as a pharmacological chaperone for mutant GALC proteins: it inhibits GALC activity in cell lysates, stabilizes GALC activity under heat denaturation, and significantly increases enzyme activity of late-onset GALC mutants in COS1 cells and patient fibroblasts. NOEV enhances maturation of GALC precursor to its mature active form. Structural modeling showed NOEV binds to the active site.","method":"In vitro GALC activity assay with NOEV, heat denaturation stability assay, patient fibroblast treatment, GALC precursor maturation assay (Western blot), molecular docking","journal":"Journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical assays demonstrating chaperone mechanism including precursor maturation, single lab","pmids":["26108143"],"is_preprint":false},{"year":2025,"finding":"In a zebrafish model, galcb (but not galca) knockout dramatically decreases total GALC activity. Galcb KO zebrafish accumulate lactosylceramide (LacCer) rather than predominantly psychosine in the brain. Intraventricular injection of LacCer upregulates proinflammatory markers and increases macrophage infiltration, identifying LacCer as a potential neuroinflammatory metabolite in GALC deficiency.","method":"CRISPR/Cas9 zebrafish knockout, GALC activity assay, targeted lipidomic analysis, intraventricular LacCer injection, immunohistochemistry, gene expression analysis","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model with lipidomic substrate identification and LacCer injection demonstrating neuroinflammatory role, single lab","pmids":["40305757"],"is_preprint":false},{"year":2024,"finding":"31 clinically-relevant GALC missense variant proteins were assessed: 26 reduced GALC activity by 92-100% vs. wild-type. Residual GALC activity strongly correlates with mature, lysosomal GALC protein levels (Pearson r=0.93). Many low-activity missense variants do not correspondingly impair GALC secretion, indicating mis-trafficking to lysosomes is a separable defect. GALC activity correlates with clinical disease severity based on age of onset (Pearson r=0.98 for homozygous missense). Psychosine levels were negatively correlated with GALC activity among pathogenic variants.","method":"CRISPR-Cas9 GALC-KO human oligodendrocytic cell line, transient expression assays, GALC activity assay, GALC secretion assay, psychosine quantification by mass spectrometry","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — comprehensive panel in GALC-KO human cell line with multiple orthogonal assays, preprint not peer-reviewed","pmids":["39464077"],"is_preprint":true},{"year":2020,"finding":"GALC overexpression in fibroblasts induces cell cycle arrest and upregulation of p16, p21, and p53, with downregulation of hTERT, driving a senescent phenotype. Senescent GALC-overexpressing fibroblasts in co-culture significantly increase colorectal cancer cell proliferation and migration.","method":"GALC overexpression in fibroblasts, co-culture with CRC cells, cell cycle analysis, gene expression for p16/p21/p53/hTERT, proliferation and migration assays","journal":"Frontiers in Oncology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, overexpression system, non-physiological context, limited mechanistic pathway placement for the canonical GALC enzyme function","pmids":["32318333"],"is_preprint":false},{"year":2020,"finding":"GALC knockout using CRISPR-Cas9 in neuronal cell models did not lead to alpha-synuclein accumulation, arguing against a direct causal relationship between GALC loss-of-function and alpha-synuclein aggregation.","method":"CRISPR-Cas9 GALC knockout, alpha-synuclein immunostaining/Western blot","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genetic KO with specific molecular readout; this is a negative result for alpha-synuclein accumulation upon GALC KO","pmids":["36370000"],"is_preprint":false},{"year":2025,"finding":"Heterozygous loss-of-function mutations in GALC have a gene-dosage effect on Aβ40 levels in brain interstitial fluid in C57BL/6 mice and significantly increase Aβ plaque formation in the 5xFAD mouse model of AD, placing GALC lysosomal activity in the pathway regulating amyloid processing.","method":"Heterozygous GALC mouse model, microdialysis for brain interstitial Aβ40, Aβ plaque quantification in 5xFAD/GALC+/- mice","journal":"bioRxiv (preprint)","confidence":"Low","confidence_rationale":"Tier 3 / Weak — preprint, single lab, gene-dosage effect on Aβ measured but mechanism not elucidated, part of a multi-gene survey","pmids":[],"is_preprint":true},{"year":2025,"finding":"Recombinant murine GALC (rm-GALC) at physiological dose restores dose-dependent enzymatic activity in KD primary cells without adverse viability effects, and restores autophagic function (normalized LC3 and p62 markers). Supra-physiological GALC doses impair autophagy and decrease cell viability, indicating that precise dosing of GALC is required for lysosomal-autophagic pathway homeostasis.","method":"HEK293T-expressed recombinant GALC purification, in vitro enzyme replacement in KD primary cells, GALC activity assay, LC3/p62 immunoblotting, cell viability assay","journal":"Advanced Biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vitro enzymatic replacement with multiple functional readouts including autophagic markers, single lab","pmids":["40590240"],"is_preprint":false}],"current_model":"GALC is a lysosomal β-galactosidase that degrades galactosphingolipids (galactosylceramide, psychosine/galactosylsphingosine, and lactosylceramide) by cleaving their β-galactosyl headgroups from ceramide tails; it requires the co-factor saposin SapA, with which it forms a heterotetramer creating a channel connecting the active site to SapA's hydrophobic cavity; after synthesis as a precursor it traffics to the lysosome where it is proteolytically processed to a mature form, a step disrupted by many disease-causing missense mutations; GALC is also secreted and can be taken up by neighboring cells via partially M6P receptor-dependent cross-correction; in macrophages/microphages GALC is required to degrade myelin-derived galactosylceramide, and its absence transforms these cells into globoid cells driving neuroinflammation; heterozygous GALC loss impairs microglial myelin debris clearance (reduced Trem2, phagocytosis) and remyelination; the gene is regulated by a GC-rich promoter with Sp1/YY1 elements and contains inhibitory intronic sequences that limit expression; and nonsense mutations trigger NMD to eliminate GALC mRNA."},"narrative":{"mechanistic_narrative":"GALC is a lysosomal β-galactosidase that catalyzes the hydrolysis of galactolipids—including galactosylceramide (galactocerebroside) and galactosylsphingosine (psychosine)—removing their β-galactosyl headgroups from the ceramide backbone [PMID:7601472]. To act on these amphipathic substrates, GALC partners with the saposin SapA, forming a heterotetramer in which an open channel connects the GALC active site to SapA's hydrophobic cavity, allowing a soluble hydrolase to access the buried glycosyl headgroup of membrane-embedded glycosphingolipids [PMID:29323104]. Beyond galactosylceramide and psychosine, GALC deficiency drives accumulation of lactosylceramide, which itself acts as a neuroinflammatory metabolite [PMID:40305757]. GALC is synthesized as a precursor that traffics to the lysosome and is proteolytically processed to its mature active form; disease-causing missense mutations frequently impair this lysosomal trafficking and maturation step, and residual GALC activity correlates tightly with mature lysosomal protein levels and with clinical severity by age of onset [PMID:26865610, PMID:23620143]. Mis-trafficking is separable from secretion, and pharmacological chaperones such as NOEV can enhance precursor maturation of late-onset mutants [PMID:26108143]. The enzyme is also secreted and taken up by neighboring cells in a partially M6P-receptor-dependent manner, enabling cross-correction in culture, though this transfer is inefficient in the peripheral nervous system in vivo [PMID:8812733, PMID:32375064, PMID:16732552]. Loss of GALC function causes Krabbe disease (globoid cell leukodystrophy): GALC-deficient macrophages cannot degrade myelin-derived galactosylceramide and are transformed into globoid cells, while GALC enzymatic activity is required for primary myelination and, in heterozygotes, for microglial myelin debris clearance (via Trem2-dependent phagocytosis) and remyelination [PMID:32375064, PMID:23620143, PMID:28575206]. Expression is constrained by a GC-rich, TATA-less promoter bearing Sp1 and YY1 elements together with inhibitory intronic sequences, and nonsense alleles are eliminated by nonsense-mediated mRNA decay [PMID:16759875, PMID:9441867].","teleology":[{"year":1995,"claim":"Establishing that GALC encodes the enzyme hydrolyzing galactosylceramide and psychosine, and defining its genomic structure, anchored the gene as the catalytic basis for galactolipid turnover.","evidence":"Gene cloning, cDNA sequencing, genomic analysis, and enzyme activity assay","pmids":["7601472"],"confidence":"High","gaps":["Did not resolve how a soluble hydrolase accesses membrane-embedded substrate","No cofactor requirement defined"]},{"year":1996,"claim":"Demonstrating secretion and uptake of active GALC by neighboring cells established cross-correction as a route for enzyme delivery and showed M6P-receptor uptake is only partly responsible.","evidence":"Retroviral transduction, [14C]-galactosylceramide metabolic labeling, lysosomal localization assay in fibroblasts","pmids":["8812733"],"confidence":"Medium","gaps":["The non-M6P uptake route was not identified","In vivo relevance not addressed at this stage"]},{"year":1996,"claim":"Functional expression of a disease-associated mutant pinpointed a single residue critical for catalysis, beginning the structure-function mapping of GALC variants.","evidence":"COS-1 expression of the canine Y158S mutant with activity measurement","pmids":["8661004"],"confidence":"Medium","gaps":["Single variant in a non-human ortholog","No structural rationale for the activity loss"]},{"year":1997,"claim":"Mapping the GALC promoter and inhibitory intronic elements explained the gene's constitutively low expression across cell types.","evidence":"CAT reporter assays with deletion constructs identifying Sp1/YY1 sites and inhibitory sequences","pmids":["9441867"],"confidence":"Medium","gaps":["Trans-acting factor binding not validated in vivo","Tissue-specific regulation not resolved"]},{"year":1999,"claim":"A mini-gene assay proved an intronic mutation causes exon 6 skipping, extending disease mechanisms beyond coding changes to splicing defects.","evidence":"GALC mini-gene transfection with RT-PCR splicing analysis","pmids":["10464649"],"confidence":"Medium","gaps":["Single mutation tested","Effect on protein/enzyme not directly measured"]},{"year":2006,"claim":"Identifying NMD-mediated decay of the twitcher nonsense allele explained the absence of GALC protein and defined a transcript-level disease mechanism.","evidence":"mRNA quantification and rescue with NMD inhibitors in twitcher Schwann cells","pmids":["16759875"],"confidence":"High","gaps":["Therapeutic relevance of NMD inhibition not established","Restricted to one nonsense allele"]},{"year":2006,"claim":"Lentivirally expressed GALC accumulating in lysosomes and correcting deficient cells via conditioned medium confirmed the secretory cross-correction route in neural cells.","evidence":"Lentiviral transduction, immunofluorescence colocalization, activity rescue of twitcher glia","pmids":["16732552"],"confidence":"Medium","gaps":["In vivo efficiency not tested here","Uptake receptor not defined"]},{"year":2013,"claim":"A knockin mutant with normal precursor but no activity dissociated catalytic loss from protein production and revealed a role for GALC in primary myelination (dysmyelination).","evidence":"GALCtwi-5J (E130K) mouse with activity, Western blot, neuropathology and EM","pmids":["23620143"],"confidence":"High","gaps":["Molecular basis of dysmyelination vs demyelination not fully resolved","Single mutation"]},{"year":2016,"claim":"Showing that severe mutants and cis-polymorphisms specifically reduce lysosomal trafficking and processing established mis-trafficking as a determinant of phenotype and explained imperfect genotype-phenotype correlation.","evidence":"Subcellular fractionation with activity assays comparing whole-cell vs lysosomal GALC across mutants","pmids":["26865610"],"confidence":"High","gaps":["Trafficking machinery interactions not mapped","Did not test in vivo CNS consequences"]},{"year":2015,"claim":"Demonstrating that NOEV chaperones mutant GALC and enhances precursor maturation provided a small-molecule strategy to rescue trafficking-defective late-onset variants.","evidence":"Activity, heat-stability, fibroblast treatment, maturation Western blot, and docking","pmids":["26108143"],"confidence":"Medium","gaps":["In vivo efficacy not shown","Limited to a subset of late-onset mutants"]},{"year":2018,"claim":"The GALC–SapA heterotetramer structure resolved how a soluble hydrolase reaches membrane-buried glycosyl headgroups through a channel to the SapA hydrophobic cavity, defining the catalytic mechanism on lipid substrates.","evidence":"Cryo-EM/crystal structure of GALC-SapA complex with functional validation","pmids":["29323104"],"confidence":"High","gaps":["Dynamics of substrate extraction not captured","Saposin specificity rules generalize beyond tested partner unverified"]},{"year":2017,"claim":"Heterozygous GALC mice exhibiting impaired remyelination, reduced microglial phagocytosis and Trem2 revealed a haploinsufficiency-linked role in myelin debris clearance.","evidence":"Cuprizone model in GALC+/- mice with phagocytosis, Trem2 readouts, and NKH-477 rescue","pmids":["28575206"],"confidence":"High","gaps":["Mechanism linking GALC dosage to Trem2 unresolved","Human heterozygote relevance not tested"]},{"year":2020,"claim":"Macrophage-specific deletion and patient transplant data established a macrophage-autonomous mechanism driving globoid cell formation and showed cross-correction fails in vivo in the PNS.","evidence":"Novel GLD mouse model, macrophage-specific GALC deletion, psychosine measurement, patient HSCT histopathology","pmids":["32375064"],"confidence":"High","gaps":["Molecular trigger of globoid transformation not fully defined","Why PNS cross-correction fails not mechanistically explained"]},{"year":2025,"claim":"A zebrafish galcb knockout that accumulates lactosylceramide rather than psychosine, with LacCer injection driving neuroinflammation, identified LacCer as a distinct neuroinflammatory metabolite of GALC deficiency.","evidence":"CRISPR zebrafish KO, lipidomics, intraventricular LacCer injection, immunohistochemistry","pmids":["40305757"],"confidence":"Medium","gaps":["Relative contribution of LacCer vs psychosine in mammals unclear","Single model organism"]},{"year":2024,"claim":"A comprehensive variant panel quantitatively linked residual activity to mature lysosomal protein levels and to clinical severity, while showing mis-trafficking is separable from secretion.","evidence":"GALC-KO human oligodendrocytic cell line, expression/activity/secretion assays, psychosine MS (preprint)","pmids":["39464077"],"confidence":"Medium","gaps":["Preprint, not peer-reviewed","Secretion-competent mis-trafficking variants mechanistically unexplained"]},{"year":2025,"claim":"Recombinant GALC enzyme replacement restored activity and autophagic markers at physiological dose but impaired them at supra-physiological dose, indicating dose-sensitive control of the lysosomal-autophagic pathway.","evidence":"Recombinant murine GALC enzyme replacement in KD primary cells with LC3/p62 immunoblot and viability assays","pmids":["40590240"],"confidence":"Medium","gaps":["Mechanism of supra-physiological toxicity unknown","In vivo dosing window not defined"]},{"year":null,"claim":"It remains unresolved how GALC dosage mechanistically couples to broader pathways implicated by emerging models (microglial Trem2 regulation, amyloid processing, autophagy homeostasis) and which lipid species dominate human neuropathology.","evidence":"Open question synthesizing genetic dosage, lipidomic, and pathway findings","pmids":[],"confidence":"Low","gaps":["No mechanistic link between GALC and amyloid processing established","Causal lipid driver in human CNS not defined","Pathway connection of GALC to senescence/cancer findings non-physiological"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,0,10,11]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[1,14]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[0,2,4,7]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,7]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[1,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,11,4]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[19]}],"complexes":["GALC-SapA heterotetramer"],"partners":["PSAP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P54803","full_name":"Galactocerebrosidase","aliases":["Galactocerebroside beta-galactosidase","Galactosylceramidase","Galactosylceramide beta-galactosidase"],"length_aa":685,"mass_kda":77.1,"function":"Hydrolyzes the galactose ester bonds of glycolipids such as galactosylceramide and galactosylsphingosine (PubMed:8281145, PubMed:8399327). Enzyme with very low activity responsible for the lysosomal catabolism of galactosylceramide, a major lipid in myelin, kidney and epithelial cells of small intestine and colon (PubMed:8281145, PubMed:8399327)","subcellular_location":"Lysosome","url":"https://www.uniprot.org/uniprotkb/P54803/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GALC","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GALC","total_profiled":1310},"omim":[{"mim_id":"621302","title":"NEURODEVELOPMENTAL DISORDER WITH SEIZURES AND JOINT LAXITY; NEDSJL","url":"https://www.omim.org/entry/621302"},{"mim_id":"613468","title":"N-ACYLSPHINGOSINE AMIDOHYDROLASE 1; ASAH1","url":"https://www.omim.org/entry/613468"},{"mim_id":"611722","title":"KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY; KRBSAPA","url":"https://www.omim.org/entry/611722"},{"mim_id":"611458","title":"GALACTOSIDASE, BETA-1; GLB1","url":"https://www.omim.org/entry/611458"},{"mim_id":"606897","title":"LYSOSOMAL TRAFFICKING REGULATOR; LYST","url":"https://www.omim.org/entry/606897"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GALC"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P54803","domains":[{"cath_id":"3.20.20.80","chopping":"56-276_292-326","consensus_level":"high","plddt":98.6054,"start":56,"end":326},{"cath_id":"2.60.120.560","chopping":"488-683","consensus_level":"high","plddt":97.4219,"start":488,"end":683}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P54803","model_url":"https://alphafold.ebi.ac.uk/files/AF-P54803-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P54803-F1-predicted_aligned_error_v6.png","plddt_mean":94.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GALC","jax_strain_url":"https://www.jax.org/strain/search?query=GALC"},"sequence":{"accession":"P54803","fasta_url":"https://rest.uniprot.org/uniprotkb/P54803.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P54803/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P54803"}},"corpus_meta":[{"pmid":"2223090","id":"PMC_2223090","title":"Two proliferative stages of the oligodendrocyte lineage (A2B5+O4- and O4+GalC-) under different mitogenic control.","date":"1990","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/2223090","citation_count":254,"is_preprint":false},{"pmid":"8405684","id":"PMC_8405684","title":"Glial cell mitogens bFGF and PDGF differentially regulate development of O4+GalC- oligodendrocyte progenitors.","date":"1993","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/8405684","citation_count":157,"is_preprint":false},{"pmid":"7581365","id":"PMC_7581365","title":"A large deletion together with a point mutation in the GALC gene is a common mutant allele in patients with infantile Krabbe disease.","date":"1995","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7581365","citation_count":99,"is_preprint":false},{"pmid":"20886637","id":"PMC_20886637","title":"Identification and characterization of 15 novel GALC gene mutations causing Krabbe disease.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20886637","citation_count":98,"is_preprint":false},{"pmid":"7601472","id":"PMC_7601472","title":"Structure and organization of the human galactocerebrosidase (GALC) gene.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7601472","citation_count":81,"is_preprint":false},{"pmid":"8634707","id":"PMC_8634707","title":"Characterization of the large deletion in the GALC gene found in patients with Krabbe disease.","date":"1995","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8634707","citation_count":75,"is_preprint":false},{"pmid":"8661004","id":"PMC_8661004","title":"Cloning of the canine GALC cDNA and identification of the mutation causing globoid cell leukodystrophy in West Highland White and Cairn terriers.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8661004","citation_count":74,"is_preprint":false},{"pmid":"7875381","id":"PMC_7875381","title":"Oligodendroblasts distinguished from O-2A glial progenitors by surface phenotype (O4+GalC-) and response to cytokines using signal transducer LIFR beta.","date":"1995","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/7875381","citation_count":74,"is_preprint":false},{"pmid":"9192853","id":"PMC_9192853","title":"Characterization of the rhesus monkey galactocerebrosidase (GALC) cDNA and gene and identification of the mutation causing globoid cell leukodystrophy (Krabbe disease) in this primate.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9192853","citation_count":60,"is_preprint":false},{"pmid":"16607461","id":"PMC_16607461","title":"Six novel mutations detected in the GALC gene in 17 Japanese patients with Krabbe disease, and new genotype-phenotype correlation.","date":"2006","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16607461","citation_count":58,"is_preprint":false},{"pmid":"32375064","id":"PMC_32375064","title":"Macrophages Expressing GALC Improve Peripheral Krabbe Disease by a Mechanism Independent of Cross-Correction.","date":"2020","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/32375064","citation_count":57,"is_preprint":false},{"pmid":"26329589","id":"PMC_26329589","title":"Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice.","date":"2015","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26329589","citation_count":53,"is_preprint":false},{"pmid":"8687180","id":"PMC_8687180","title":"Multiple mutations in the GALC gene in a patient with adult-onset Krabbe disease.","date":"1996","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/8687180","citation_count":52,"is_preprint":false},{"pmid":"23620143","id":"PMC_23620143","title":"Missense mutation in mouse GALC mimics human gene defect and offers new insights into Krabbe disease.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23620143","citation_count":49,"is_preprint":false},{"pmid":"29323104","id":"PMC_29323104","title":"The mechanism of glycosphingolipid degradation revealed by a GALC-SapA complex structure.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29323104","citation_count":48,"is_preprint":false},{"pmid":"27638599","id":"PMC_27638599","title":"Intrathecal administration of AAV/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant.","date":"2016","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/27638599","citation_count":47,"is_preprint":false},{"pmid":"25533112","id":"PMC_25533112","title":"Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features.","date":"2014","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25533112","citation_count":43,"is_preprint":false},{"pmid":"8423632","id":"PMC_8423632","title":"Transient reversion of O4+ GalC- oligodendrocyte progenitor development in response to the phorbol ester TPA.","date":"1993","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/8423632","citation_count":41,"is_preprint":false},{"pmid":"7544324","id":"PMC_7544324","title":"Elevated intracellular levels of cAMP induce olfactory ensheathing cells to express GAL-C and GFAP but not MBP.","date":"1995","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/7544324","citation_count":41,"is_preprint":false},{"pmid":"26865610","id":"PMC_26865610","title":"Altered Trafficking and Processing of GALC Mutants Correlates with Globoid Cell Leukodystrophy Severity.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26865610","citation_count":38,"is_preprint":false},{"pmid":"8812733","id":"PMC_8812733","title":"Retroviral vector-mediated transfer of the galactocerebrosidase (GALC) cDNA leads to overexpression and transfer of GALC activity to neighboring cells.","date":"1996","source":"Biochemical and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8812733","citation_count":38,"is_preprint":false},{"pmid":"17579360","id":"PMC_17579360","title":"A single mutation in the GALC gene is responsible for the majority of late onset Krabbe disease patients in the Catania (Sicily, Italy) region.","date":"2007","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/17579360","citation_count":36,"is_preprint":false},{"pmid":"8162701","id":"PMC_8162701","title":"Regional mapping of the human galactocerebrosidase gene (GALC) to 14q31 by in situ hybridization.","date":"1994","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8162701","citation_count":36,"is_preprint":false},{"pmid":"22073273","id":"PMC_22073273","title":"GALC deletions increase the risk of primary open-angle glaucoma: the role of Mendelian variants in complex disease.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22073273","citation_count":34,"is_preprint":false},{"pmid":"16732552","id":"PMC_16732552","title":"Design and optimization of lentiviral vectors for transfer of GALC expression in Twitcher brain.","date":"2006","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16732552","citation_count":33,"is_preprint":false},{"pmid":"11814461","id":"PMC_11814461","title":"Residual galactosylsphingosine (psychosine) beta-galactosidase activities and associated GALC mutations in late and very late onset Krabbe disease.","date":"2002","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11814461","citation_count":31,"is_preprint":false},{"pmid":"28575206","id":"PMC_28575206","title":"Heterozygote galactocerebrosidase (GALC) mutants have reduced remyelination and impaired myelin debris clearance following demyelinating injury.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28575206","citation_count":29,"is_preprint":false},{"pmid":"1382941","id":"PMC_1382941","title":"Stage specific, (O4+GalC-) isolated oligodendrocyte progenitors produce MBP+ myelin in vivo.","date":"1992","source":"Developmental neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/1382941","citation_count":29,"is_preprint":false},{"pmid":"25101718","id":"PMC_25101718","title":"IREB2 and GALC are associated with pulmonary artery enlargement in chronic obstructive pulmonary disease.","date":"2015","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25101718","citation_count":28,"is_preprint":false},{"pmid":"16759875","id":"PMC_16759875","title":"Suppression of galactosylceramidase (GALC) expression in the twitcher mouse model of globoid cell leukodystrophy (GLD) is caused by nonsense-mediated mRNA decay (NMD).","date":"2006","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/16759875","citation_count":28,"is_preprint":false},{"pmid":"26108143","id":"PMC_26108143","title":"Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations.","date":"2015","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26108143","citation_count":27,"is_preprint":false},{"pmid":"9266397","id":"PMC_9266397","title":"Prevalent mutations in the GALC gene of patients with Krabbe disease of Dutch and other European origin.","date":"1997","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/9266397","citation_count":27,"is_preprint":false},{"pmid":"36370000","id":"PMC_36370000","title":"GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson's disease.","date":"2023","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36370000","citation_count":26,"is_preprint":false},{"pmid":"8250040","id":"PMC_8250040","title":"Localization of the Krabbe disease gene (GALC) on chromosome 14 by multipoint linkage analysis.","date":"1993","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8250040","citation_count":22,"is_preprint":false},{"pmid":"9972877","id":"PMC_9972877","title":"Transduction of cultured oligodendrocytes from normal and twitcher mice by a retroviral vector containing human galactocerebrosidase (GALC) cDNA.","date":"1999","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/9972877","citation_count":22,"is_preprint":false},{"pmid":"33178108","id":"PMC_33178108","title":"Pathogenic Variants in GALC Gene Correlate With Late Onset Krabbe Disease and Vision Loss: Case Series and Review of Literature.","date":"2020","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33178108","citation_count":19,"is_preprint":false},{"pmid":"23462331","id":"PMC_23462331","title":"Four novel GALC gene mutations in two Chinese patients with Krabbe disease.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23462331","citation_count":17,"is_preprint":false},{"pmid":"33842284","id":"PMC_33842284","title":"Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?","date":"2021","source":"BioImpacts : BI","url":"https://pubmed.ncbi.nlm.nih.gov/33842284","citation_count":15,"is_preprint":false},{"pmid":"15781194","id":"PMC_15781194","title":"GALC transduction leads to morphological improvement of the twitcher oligodendrocytes in vivo.","date":"2005","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15781194","citation_count":15,"is_preprint":false},{"pmid":"22959700","id":"PMC_22959700","title":"Isolated pyramidal tract impairment in the central nervous system of adult-onset Krabbe disease with novel mutations in the GALC gene.","date":"2012","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/22959700","citation_count":15,"is_preprint":false},{"pmid":"32318333","id":"PMC_32318333","title":"GALC Triggers Tumorigenicity of Colorectal Cancer via Senescent Fibroblasts.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32318333","citation_count":14,"is_preprint":false},{"pmid":"32677356","id":"PMC_32677356","title":"Adult-onset Krabbe disease due to a homozygous GALC mutation without abnormal signals on an MRI in a consanguineous family: A case report.","date":"2020","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32677356","citation_count":13,"is_preprint":false},{"pmid":"23276707","id":"PMC_23276707","title":"A novel homozygous GALC mutation: very early onset and rapidly progressive Krabbe disease.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23276707","citation_count":11,"is_preprint":false},{"pmid":"29136295","id":"PMC_29136295","title":"Genomewide association study identifies GALC as susceptibility gene for mucous membrane pemphigoid.","date":"2017","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/29136295","citation_count":11,"is_preprint":false},{"pmid":"10464649","id":"PMC_10464649","title":"Characterization of the GALC gene in three Japanese patients with adult-onset Krabbe disease.","date":"1997","source":"Genetic testing","url":"https://pubmed.ncbi.nlm.nih.gov/10464649","citation_count":10,"is_preprint":false},{"pmid":"35013804","id":"PMC_35013804","title":"A novel compound heterozygous mutation in GALC associated with adult-onset Krabbe disease: case report and literature review.","date":"2022","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/35013804","citation_count":9,"is_preprint":false},{"pmid":"32186243","id":"PMC_32186243","title":"Molecular dynamics simulations to decipher the structural and functional consequences of pathogenic missense mutations in the galactosylceramidase (GALC) protein causing Krabbe's disease.","date":"2020","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/32186243","citation_count":9,"is_preprint":false},{"pmid":"9441867","id":"PMC_9441867","title":"Analysis of the 5' flanking region of the human galactocerebrosidase (GALC) gene.","date":"1997","source":"Biochemical and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9441867","citation_count":8,"is_preprint":false},{"pmid":"37628569","id":"PMC_37628569","title":"Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/37628569","citation_count":7,"is_preprint":false},{"pmid":"35654103","id":"PMC_35654103","title":"A novel GALC gene mutation associated with adult-onset Krabbe disease: a case report.","date":"2022","source":"Neurocase","url":"https://pubmed.ncbi.nlm.nih.gov/35654103","citation_count":7,"is_preprint":false},{"pmid":"38515343","id":"PMC_38515343","title":"Clinical feature, GALC variant spectrum, and genotype-phenotype correlation in Korean Krabbe disease patients: Multicenter experience over 13 years.","date":"2024","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38515343","citation_count":7,"is_preprint":false},{"pmid":"37111381","id":"PMC_37111381","title":"rAAV2-Mediated Restoration of GALC in Neural Stem Cells from Krabbe Patient-Derived iPSCs.","date":"2023","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37111381","citation_count":7,"is_preprint":false},{"pmid":"31185936","id":"PMC_31185936","title":"GALC mutations in Chinese patients with late-onset Krabbe disease: a case report.","date":"2019","source":"BMC neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31185936","citation_count":7,"is_preprint":false},{"pmid":"26567009","id":"PMC_26567009","title":"Clinical and molecular report of novel GALC mutations in Moroccan patient with Krabbe disease: case report.","date":"2015","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/26567009","citation_count":7,"is_preprint":false},{"pmid":"32973651","id":"PMC_32973651","title":"Novel GALC Mutations Cause Adult-Onset Krabbe Disease With Myelopathy in Two Chinese Families: Case Reports and Literature Review.","date":"2020","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32973651","citation_count":7,"is_preprint":false},{"pmid":"28109651","id":"PMC_28109651","title":"Late onset Krabbe disease due to the new GALC p.Ala543Pro mutation, with intriguingly high residual GALC activity in vitro.","date":"2017","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/28109651","citation_count":6,"is_preprint":false},{"pmid":"33424556","id":"PMC_33424556","title":"AAV-Mediated GALC Gene Therapy Rescues Alpha-Synucleinopathy in the Spinal Cord of a Leukodystrophic Lysosomal Storage Disease Mouse Model.","date":"2020","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33424556","citation_count":6,"is_preprint":false},{"pmid":"40391866","id":"PMC_40391866","title":"High Prevalence of GALC Gene Variants in Adults With Neurodegenerative Conditions.","date":"2025","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40391866","citation_count":5,"is_preprint":false},{"pmid":"26178533","id":"PMC_26178533","title":"GALC gene is downregulated by promoter hypermethylation in Epstein-Barr virus-associated nasopharyngeal carcinoma.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26178533","citation_count":5,"is_preprint":false},{"pmid":"32304783","id":"PMC_32304783","title":"Allele frequency analysis of GALC gene causing Krabbe disease in human and its codon usage.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32304783","citation_count":4,"is_preprint":false},{"pmid":"36551902","id":"PMC_36551902","title":"Reliable and Fast Genotyping Protocol for Galactosylceramidase (Galc) in the Twitcher (Twi) Mouse.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36551902","citation_count":4,"is_preprint":false},{"pmid":"38762762","id":"PMC_38762762","title":"Splicing mutations of GALC in adult patient with adult-onset Krabbe disease: case report and review of literature.","date":"2024","source":"Neurocase","url":"https://pubmed.ncbi.nlm.nih.gov/38762762","citation_count":4,"is_preprint":false},{"pmid":"22704718","id":"PMC_22704718","title":"Array CGH improves detection of mutations in the GALC gene associated with Krabbe disease.","date":"2012","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22704718","citation_count":4,"is_preprint":false},{"pmid":"36270068","id":"PMC_36270068","title":"Production and characterization of human induced pluripotent stem cell line (PUMCi002-A) from a Krabbe patient related control to study disease mechanisms associated with GALC mutation.","date":"2022","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/36270068","citation_count":4,"is_preprint":false},{"pmid":"27442402","id":"PMC_27442402","title":"Compound Galactosylceramidase Gene (GALC) Heterozygosity in a Boy with Infantile Krabbe Disease (KD).","date":"2015","source":"Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)","url":"https://pubmed.ncbi.nlm.nih.gov/27442402","citation_count":4,"is_preprint":false},{"pmid":"30323943","id":"PMC_30323943","title":"Exonic deletions in GALC are frequent in Japanese globoid-cell leukodystrophy patients.","date":"2018","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/30323943","citation_count":4,"is_preprint":false},{"pmid":"40305757","id":"PMC_40305757","title":"Brain accumulation of lactosylceramide characterizes GALC deficiency in a zebrafish model of Krabbe disease.","date":"2025","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40305757","citation_count":3,"is_preprint":false},{"pmid":"40590240","id":"PMC_40590240","title":"Investigating the Cellular Effects of GALC Dosing in Enzyme Replacement Therapy for Krabbe Disease Supports the Role of Nanomedicine.","date":"2025","source":"Advanced biology","url":"https://pubmed.ncbi.nlm.nih.gov/40590240","citation_count":3,"is_preprint":false},{"pmid":"34765479","id":"PMC_34765479","title":"Compound heterozygous pathogenic variants in the GALC gene cause infant-onset Krabbe disease.","date":"2021","source":"Translational pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/34765479","citation_count":2,"is_preprint":false},{"pmid":"40692539","id":"PMC_40692539","title":"Amelioration of Inflammation and Metabolic Blockage in GALC Deficient Mice After Enzyme Replacement Therapy via Extracellular Vesicles.","date":"2025","source":"International journal of nanomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/40692539","citation_count":1,"is_preprint":false},{"pmid":"41086929","id":"PMC_41086929","title":"Beyond Krabbe disease, the intriguing connection of galactocerebrosidase (GALC) with nervous system illness: A novel risk factor?","date":"2025","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/41086929","citation_count":1,"is_preprint":false},{"pmid":"39464077","id":"PMC_39464077","title":"Expression study of Krabbe Disease GALC missense variants - Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39464077","citation_count":1,"is_preprint":false},{"pmid":"40943566","id":"PMC_40943566","title":"Molecular Characterization of the GALC Mutation Thr112Ala Causing Krabbe Disease.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40943566","citation_count":1,"is_preprint":false},{"pmid":"30209698","id":"PMC_30209698","title":"A novel homozygous GALC variant has been associated with Krabbe disease in a consanguineous family.","date":"2018","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/30209698","citation_count":1,"is_preprint":false},{"pmid":"41463122","id":"PMC_41463122","title":"Abnormal Splicing of GALC Transcripts Underlies Unusual Cases of Krabbe Disease.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/41463122","citation_count":0,"is_preprint":false},{"pmid":"42169729","id":"PMC_42169729","title":"Molecular Dynamics Simulations of 4 GALC Variants Causing Krabbe Disease.","date":"2026","source":"Computational and structural biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/42169729","citation_count":0,"is_preprint":false},{"pmid":"42026681","id":"PMC_42026681","title":"In vivo adenine base editing of mutant Galc gene ameliorates Krabbe disease progression.","date":"2026","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/42026681","citation_count":0,"is_preprint":false},{"pmid":"10424145","id":"PMC_10424145","title":"[A case of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome with positive anti-galactocerebroside (Gal-C) IgM antibody].","date":"1999","source":"Rinsho shinkeigaku = Clinical neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10424145","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.10.17.618938","title":"Expression study of Krabbe Disease  <i>GALC</i>  missense variants – Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels","date":"2024-10-17","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.17.618938","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.16.623962","title":"Haploinsufficiency of lysosomal enzyme genes in Alzheimer’s disease","date":"2024-11-18","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.16.623962","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.19.604372","title":"Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease","date":"2024-07-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.19.604372","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41478,"output_tokens":5106,"usd":0.100512,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13327,"output_tokens":4612,"usd":0.090968,"stage2_stop_reason":"end_turn"},"total_usd":0.19148,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"GALC and the saposin SapA form a heterotetramer complex that creates an open channel connecting the GALC active site to the SapA hydrophobic cavity, revealing the mechanism by which a soluble lysosomal hydrolase cleaves the polar glycosyl headgroups of glycosphingolipids (galactocerebroside) from their hydrophobic ceramide tails. This structure also defines how specificity of saposin binding to hydrolases is encoded.\",\n      \"method\": \"Cryo-EM/crystal structure of GALC-SapA complex with functional validation\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic structure of the complex with functional mechanistic interpretation, multiple orthogonal structural methods in a single rigorous study\",\n      \"pmids\": [\"29323104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"GALC catalyzes the lysosomal hydrolysis of galactolipids including galactosylceramide (galactocerebroside) and galactosylsphingosine (psychosine). The gene spans ~60 kb and consists of 17 exons, establishing the genomic organization relevant to understanding enzyme structure-function.\",\n      \"method\": \"Gene cloning, cDNA sequencing, genomic library analysis, enzyme activity assay\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical characterization of enzymatic activity and gene structure, replicated across multiple studies\",\n      \"pmids\": [\"7601472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"GALC is secreted into the media by transduced fibroblasts and taken up by untransduced neighboring cells. Mannose-6-phosphate receptor-mediated uptake is only partially responsible for the efficient transfer of GALC to neighboring cells (cross-correction). The transferred GALC is localized to lysosomes and is functionally active, as demonstrated by normal metabolism of [14C]stearic acid-labeled galactosylceramide.\",\n      \"method\": \"Retroviral transduction, GALC activity assay, [14C]-substrate metabolic labeling, lysosomal localization assay\",\n      \"journal\": \"Biochemical and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays in a single lab demonstrating lysosomal localization and partial M6P-receptor-dependent cross-correction\",\n      \"pmids\": [\"8812733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cross-correction of GALC does not occur efficiently in vivo in the peripheral nervous system. Galc-deficient Schwann cells autonomously produce psychosine. Galc-deficient macrophages cannot degrade myelin and are transformed into globoid cells upon exposure to galactosylceramide, producing a more severe GLD phenotype. Hematopoietic stem cell transplantation reduces globoid cells in patient nerves via phagocytic activity of healthy macrophages rather than cross-correction.\",\n      \"method\": \"Novel GLD mouse model, macrophage-specific GALC deletion, psychosine measurement, histopathology, hematopoietic stem cell transplantation in patients\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models and orthogonal methods (cell biology, mouse models, patient tissue) establishing macrophage-autonomous mechanism\",\n      \"pmids\": [\"32375064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Infantile-onset GALC mutants show reduced trafficking to lysosomes and reduced proteolytic processing compared to later-onset mutants when measured in the lysosomal fraction, even when total cell lysate activity appears similar. Cis-polymorphisms in GALC also affect lysosomal trafficking and processing, explaining imperfect genotype-phenotype correlations.\",\n      \"method\": \"Subcellular fractionation, GALC activity assay in lysosomal vs. whole-cell fractions, site-directed mutagenesis, cell transfection\",\n      \"journal\": \"The Journal of Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct lysosomal fractionation with enzymatic quantification, multiple mutants and polymorphisms tested in parallel with functional consequences\",\n      \"pmids\": [\"26865610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Expression studies in COS-1 cells demonstrated that the A to C transversion at cDNA position 473 (Y158S) is the disease-causing mutation in canine GLD, establishing this specific amino acid as critical for GALC enzymatic activity.\",\n      \"method\": \"COS-1 cell expression assay, site-directed mutagenesis, GALC activity measurement\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro expression assay with functional activity readout, single lab\",\n      \"pmids\": [\"8661004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The twitcher mouse has a premature stop codon (W339X) in GALC that triggers nonsense-mediated mRNA decay (NMD), resulting in reduced GALC transcript levels proportional to the number of twitcher alleles. NMD inhibitors (anisomycin, emetine, puromycin) restored GALC transcript levels in twitcher-derived Schwann cells, confirming NMD as the mechanism by which no GALC protein is detected.\",\n      \"method\": \"RT-PCR/Northern blot for mRNA quantification, NMD inhibitor treatment, immunocytochemistry, Western blot\",\n      \"journal\": \"Neurobiology of Disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple NMD inhibitors tested, dose-allele relationship established, multiple orthogonal methods confirming NMD mechanism\",\n      \"pmids\": [\"16759875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"GALC expressed from lentiviral vectors accumulates in lysosomes of transduced neural cells and is also secreted to the extracellular medium. Conditioned GALC-containing medium corrects GALC deficiency in non-transduced twitcher glial cultures, confirming the secretory pathway of lysosomal enzyme delivery.\",\n      \"method\": \"Lentiviral transduction, immunofluorescence for lysosomal colocalization, GALC activity assay in conditioned medium and non-transduced cells\",\n      \"journal\": \"The journal of gene medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct lysosomal localization demonstrated by immunofluorescence and functional cross-correction in vitro, single lab\",\n      \"pmids\": [\"16732552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The 5' flanking region of the human GALC gene is GC-rich with no CAAT or TATA sequences, contains Sp1 and YY1 binding sites, and a construct spanning nucleotides -176 to -24 has the strongest promoter activity. Inhibitory sequences exist immediately upstream of the promoter and in the first 234 nt of intron 1, which together with a suboptimal nucleotide at +4 explain the low levels of GALC protein in all cell types.\",\n      \"method\": \"Chloramphenicol acetyltransferase reporter gene assay with deletion constructs, promoter activity measurement\",\n      \"journal\": \"Biochemical and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay with multiple deletion constructs identifying active and inhibitory elements, single lab\",\n      \"pmids\": [\"9441867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"An intronic mutation IVS6+5G>A in the GALC gene causes exon 6 skipping. Transfection of a GALC mini-gene harboring this mutation proved that this specific intronic change is the cause of exon 6 skipping, resulting in loss of function.\",\n      \"method\": \"GALC mini-gene transfection assay, RT-PCR analysis of splicing\",\n      \"journal\": \"Genetic testing\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct mini-gene functional splicing assay demonstrating causality of the intronic mutation, single lab\",\n      \"pmids\": [\"10464649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The novel GALC p.Gly41Ser substitution abolishes catalytic activity of galactocerebrosidase, as demonstrated by expression studies, and is responsible for late-onset Krabbe disease in a Sicilian founder population.\",\n      \"method\": \"Expression studies (cell transfection), GALC enzymatic activity assay\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — single lab, in vitro expression activity assay confirming loss of catalytic function\",\n      \"pmids\": [\"17579360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The GALCtwi-5J missense mutation (E130K) causes loss of enzymatic activity despite normal levels of precursor protein, indicating the mutation disrupts catalytic function rather than protein production. The PNS is severely hypomyelinated and lacks large diameter axons (dysmyelination rather than demyelination), supporting a role for GALC enzymatic activity in primary myelination.\",\n      \"method\": \"Mouse model characterization, GALC activity assay, Western blot for precursor protein, neuropathology, electron microscopy\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockin mouse model with direct enzymatic and protein quantification, multiple orthogonal neuropathological methods\",\n      \"pmids\": [\"23620143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Heterozygous GALC mutant mice (GALC+/-) have reduced myelin debris clearance and diminished remyelination after cuprizone-induced demyelination. The microglial phagocytic response and elevation of Trem2 (necessary for clearing damaged myelin) are markedly reduced in GALC+/- animals. These defects were corrected in vitro by NKH-477 treatment.\",\n      \"method\": \"Cuprizone demyelination model in GALC+/- mice, histological analysis of remyelination, microglial phagocytosis assay, Trem2 expression analysis, pharmacological rescue\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic mouse model with defined demyelinating insult, multiple outcome measures (remyelination, phagocytosis, Trem2), pharmacological rescue in vitro\",\n      \"pmids\": [\"28575206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"N-octyl-4-epi-β-valienamine (NOEV) acts as a pharmacological chaperone for mutant GALC proteins: it inhibits GALC activity in cell lysates, stabilizes GALC activity under heat denaturation, and significantly increases enzyme activity of late-onset GALC mutants in COS1 cells and patient fibroblasts. NOEV enhances maturation of GALC precursor to its mature active form. Structural modeling showed NOEV binds to the active site.\",\n      \"method\": \"In vitro GALC activity assay with NOEV, heat denaturation stability assay, patient fibroblast treatment, GALC precursor maturation assay (Western blot), molecular docking\",\n      \"journal\": \"Journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical assays demonstrating chaperone mechanism including precursor maturation, single lab\",\n      \"pmids\": [\"26108143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In a zebrafish model, galcb (but not galca) knockout dramatically decreases total GALC activity. Galcb KO zebrafish accumulate lactosylceramide (LacCer) rather than predominantly psychosine in the brain. Intraventricular injection of LacCer upregulates proinflammatory markers and increases macrophage infiltration, identifying LacCer as a potential neuroinflammatory metabolite in GALC deficiency.\",\n      \"method\": \"CRISPR/Cas9 zebrafish knockout, GALC activity assay, targeted lipidomic analysis, intraventricular LacCer injection, immunohistochemistry, gene expression analysis\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model with lipidomic substrate identification and LacCer injection demonstrating neuroinflammatory role, single lab\",\n      \"pmids\": [\"40305757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"31 clinically-relevant GALC missense variant proteins were assessed: 26 reduced GALC activity by 92-100% vs. wild-type. Residual GALC activity strongly correlates with mature, lysosomal GALC protein levels (Pearson r=0.93). Many low-activity missense variants do not correspondingly impair GALC secretion, indicating mis-trafficking to lysosomes is a separable defect. GALC activity correlates with clinical disease severity based on age of onset (Pearson r=0.98 for homozygous missense). Psychosine levels were negatively correlated with GALC activity among pathogenic variants.\",\n      \"method\": \"CRISPR-Cas9 GALC-KO human oligodendrocytic cell line, transient expression assays, GALC activity assay, GALC secretion assay, psychosine quantification by mass spectrometry\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — comprehensive panel in GALC-KO human cell line with multiple orthogonal assays, preprint not peer-reviewed\",\n      \"pmids\": [\"39464077\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GALC overexpression in fibroblasts induces cell cycle arrest and upregulation of p16, p21, and p53, with downregulation of hTERT, driving a senescent phenotype. Senescent GALC-overexpressing fibroblasts in co-culture significantly increase colorectal cancer cell proliferation and migration.\",\n      \"method\": \"GALC overexpression in fibroblasts, co-culture with CRC cells, cell cycle analysis, gene expression for p16/p21/p53/hTERT, proliferation and migration assays\",\n      \"journal\": \"Frontiers in Oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, overexpression system, non-physiological context, limited mechanistic pathway placement for the canonical GALC enzyme function\",\n      \"pmids\": [\"32318333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GALC knockout using CRISPR-Cas9 in neuronal cell models did not lead to alpha-synuclein accumulation, arguing against a direct causal relationship between GALC loss-of-function and alpha-synuclein aggregation.\",\n      \"method\": \"CRISPR-Cas9 GALC knockout, alpha-synuclein immunostaining/Western blot\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genetic KO with specific molecular readout; this is a negative result for alpha-synuclein accumulation upon GALC KO\",\n      \"pmids\": [\"36370000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Heterozygous loss-of-function mutations in GALC have a gene-dosage effect on Aβ40 levels in brain interstitial fluid in C57BL/6 mice and significantly increase Aβ plaque formation in the 5xFAD mouse model of AD, placing GALC lysosomal activity in the pathway regulating amyloid processing.\",\n      \"method\": \"Heterozygous GALC mouse model, microdialysis for brain interstitial Aβ40, Aβ plaque quantification in 5xFAD/GALC+/- mice\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — preprint, single lab, gene-dosage effect on Aβ measured but mechanism not elucidated, part of a multi-gene survey\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Recombinant murine GALC (rm-GALC) at physiological dose restores dose-dependent enzymatic activity in KD primary cells without adverse viability effects, and restores autophagic function (normalized LC3 and p62 markers). Supra-physiological GALC doses impair autophagy and decrease cell viability, indicating that precise dosing of GALC is required for lysosomal-autophagic pathway homeostasis.\",\n      \"method\": \"HEK293T-expressed recombinant GALC purification, in vitro enzyme replacement in KD primary cells, GALC activity assay, LC3/p62 immunoblotting, cell viability assay\",\n      \"journal\": \"Advanced Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vitro enzymatic replacement with multiple functional readouts including autophagic markers, single lab\",\n      \"pmids\": [\"40590240\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GALC is a lysosomal β-galactosidase that degrades galactosphingolipids (galactosylceramide, psychosine/galactosylsphingosine, and lactosylceramide) by cleaving their β-galactosyl headgroups from ceramide tails; it requires the co-factor saposin SapA, with which it forms a heterotetramer creating a channel connecting the active site to SapA's hydrophobic cavity; after synthesis as a precursor it traffics to the lysosome where it is proteolytically processed to a mature form, a step disrupted by many disease-causing missense mutations; GALC is also secreted and can be taken up by neighboring cells via partially M6P receptor-dependent cross-correction; in macrophages/microphages GALC is required to degrade myelin-derived galactosylceramide, and its absence transforms these cells into globoid cells driving neuroinflammation; heterozygous GALC loss impairs microglial myelin debris clearance (reduced Trem2, phagocytosis) and remyelination; the gene is regulated by a GC-rich promoter with Sp1/YY1 elements and contains inhibitory intronic sequences that limit expression; and nonsense mutations trigger NMD to eliminate GALC mRNA.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GALC is a lysosomal β-galactosidase that catalyzes the hydrolysis of galactolipids—including galactosylceramide (galactocerebroside) and galactosylsphingosine (psychosine)—removing their β-galactosyl headgroups from the ceramide backbone [#1]. To act on these amphipathic substrates, GALC partners with the saposin SapA, forming a heterotetramer in which an open channel connects the GALC active site to SapA's hydrophobic cavity, allowing a soluble hydrolase to access the buried glycosyl headgroup of membrane-embedded glycosphingolipids [#0]. Beyond galactosylceramide and psychosine, GALC deficiency drives accumulation of lactosylceramide, which itself acts as a neuroinflammatory metabolite [#14]. GALC is synthesized as a precursor that traffics to the lysosome and is proteolytically processed to its mature active form; disease-causing missense mutations frequently impair this lysosomal trafficking and maturation step, and residual GALC activity correlates tightly with mature lysosomal protein levels and with clinical severity by age of onset [#4, #11]. Mis-trafficking is separable from secretion, and pharmacological chaperones such as NOEV can enhance precursor maturation of late-onset mutants [#13]. The enzyme is also secreted and taken up by neighboring cells in a partially M6P-receptor-dependent manner, enabling cross-correction in culture, though this transfer is inefficient in the peripheral nervous system in vivo [#2, #3, #7]. Loss of GALC function causes Krabbe disease (globoid cell leukodystrophy): GALC-deficient macrophages cannot degrade myelin-derived galactosylceramide and are transformed into globoid cells, while GALC enzymatic activity is required for primary myelination and, in heterozygotes, for microglial myelin debris clearance (via Trem2-dependent phagocytosis) and remyelination [#3, #11, #12]. Expression is constrained by a GC-rich, TATA-less promoter bearing Sp1 and YY1 elements together with inhibitory intronic sequences, and nonsense alleles are eliminated by nonsense-mediated mRNA decay [#6, #8].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that GALC encodes the enzyme hydrolyzing galactosylceramide and psychosine, and defining its genomic structure, anchored the gene as the catalytic basis for galactolipid turnover.\",\n      \"evidence\": \"Gene cloning, cDNA sequencing, genomic analysis, and enzyme activity assay\",\n      \"pmids\": [\"7601472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how a soluble hydrolase accesses membrane-embedded substrate\", \"No cofactor requirement defined\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrating secretion and uptake of active GALC by neighboring cells established cross-correction as a route for enzyme delivery and showed M6P-receptor uptake is only partly responsible.\",\n      \"evidence\": \"Retroviral transduction, [14C]-galactosylceramide metabolic labeling, lysosomal localization assay in fibroblasts\",\n      \"pmids\": [\"8812733\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The non-M6P uptake route was not identified\", \"In vivo relevance not addressed at this stage\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Functional expression of a disease-associated mutant pinpointed a single residue critical for catalysis, beginning the structure-function mapping of GALC variants.\",\n      \"evidence\": \"COS-1 expression of the canine Y158S mutant with activity measurement\",\n      \"pmids\": [\"8661004\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single variant in a non-human ortholog\", \"No structural rationale for the activity loss\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Mapping the GALC promoter and inhibitory intronic elements explained the gene's constitutively low expression across cell types.\",\n      \"evidence\": \"CAT reporter assays with deletion constructs identifying Sp1/YY1 sites and inhibitory sequences\",\n      \"pmids\": [\"9441867\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Trans-acting factor binding not validated in vivo\", \"Tissue-specific regulation not resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"A mini-gene assay proved an intronic mutation causes exon 6 skipping, extending disease mechanisms beyond coding changes to splicing defects.\",\n      \"evidence\": \"GALC mini-gene transfection with RT-PCR splicing analysis\",\n      \"pmids\": [\"10464649\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single mutation tested\", \"Effect on protein/enzyme not directly measured\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying NMD-mediated decay of the twitcher nonsense allele explained the absence of GALC protein and defined a transcript-level disease mechanism.\",\n      \"evidence\": \"mRNA quantification and rescue with NMD inhibitors in twitcher Schwann cells\",\n      \"pmids\": [\"16759875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic relevance of NMD inhibition not established\", \"Restricted to one nonsense allele\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Lentivirally expressed GALC accumulating in lysosomes and correcting deficient cells via conditioned medium confirmed the secretory cross-correction route in neural cells.\",\n      \"evidence\": \"Lentiviral transduction, immunofluorescence colocalization, activity rescue of twitcher glia\",\n      \"pmids\": [\"16732552\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo efficiency not tested here\", \"Uptake receptor not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A knockin mutant with normal precursor but no activity dissociated catalytic loss from protein production and revealed a role for GALC in primary myelination (dysmyelination).\",\n      \"evidence\": \"GALCtwi-5J (E130K) mouse with activity, Western blot, neuropathology and EM\",\n      \"pmids\": [\"23620143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of dysmyelination vs demyelination not fully resolved\", \"Single mutation\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showing that severe mutants and cis-polymorphisms specifically reduce lysosomal trafficking and processing established mis-trafficking as a determinant of phenotype and explained imperfect genotype-phenotype correlation.\",\n      \"evidence\": \"Subcellular fractionation with activity assays comparing whole-cell vs lysosomal GALC across mutants\",\n      \"pmids\": [\"26865610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trafficking machinery interactions not mapped\", \"Did not test in vivo CNS consequences\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that NOEV chaperones mutant GALC and enhances precursor maturation provided a small-molecule strategy to rescue trafficking-defective late-onset variants.\",\n      \"evidence\": \"Activity, heat-stability, fibroblast treatment, maturation Western blot, and docking\",\n      \"pmids\": [\"26108143\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo efficacy not shown\", \"Limited to a subset of late-onset mutants\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The GALC–SapA heterotetramer structure resolved how a soluble hydrolase reaches membrane-buried glycosyl headgroups through a channel to the SapA hydrophobic cavity, defining the catalytic mechanism on lipid substrates.\",\n      \"evidence\": \"Cryo-EM/crystal structure of GALC-SapA complex with functional validation\",\n      \"pmids\": [\"29323104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics of substrate extraction not captured\", \"Saposin specificity rules generalize beyond tested partner unverified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Heterozygous GALC mice exhibiting impaired remyelination, reduced microglial phagocytosis and Trem2 revealed a haploinsufficiency-linked role in myelin debris clearance.\",\n      \"evidence\": \"Cuprizone model in GALC+/- mice with phagocytosis, Trem2 readouts, and NKH-477 rescue\",\n      \"pmids\": [\"28575206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking GALC dosage to Trem2 unresolved\", \"Human heterozygote relevance not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Macrophage-specific deletion and patient transplant data established a macrophage-autonomous mechanism driving globoid cell formation and showed cross-correction fails in vivo in the PNS.\",\n      \"evidence\": \"Novel GLD mouse model, macrophage-specific GALC deletion, psychosine measurement, patient HSCT histopathology\",\n      \"pmids\": [\"32375064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular trigger of globoid transformation not fully defined\", \"Why PNS cross-correction fails not mechanistically explained\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A zebrafish galcb knockout that accumulates lactosylceramide rather than psychosine, with LacCer injection driving neuroinflammation, identified LacCer as a distinct neuroinflammatory metabolite of GALC deficiency.\",\n      \"evidence\": \"CRISPR zebrafish KO, lipidomics, intraventricular LacCer injection, immunohistochemistry\",\n      \"pmids\": [\"40305757\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of LacCer vs psychosine in mammals unclear\", \"Single model organism\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A comprehensive variant panel quantitatively linked residual activity to mature lysosomal protein levels and to clinical severity, while showing mis-trafficking is separable from secretion.\",\n      \"evidence\": \"GALC-KO human oligodendrocytic cell line, expression/activity/secretion assays, psychosine MS (preprint)\",\n      \"pmids\": [\"39464077\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not peer-reviewed\", \"Secretion-competent mis-trafficking variants mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Recombinant GALC enzyme replacement restored activity and autophagic markers at physiological dose but impaired them at supra-physiological dose, indicating dose-sensitive control of the lysosomal-autophagic pathway.\",\n      \"evidence\": \"Recombinant murine GALC enzyme replacement in KD primary cells with LC3/p62 immunoblot and viability assays\",\n      \"pmids\": [\"40590240\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of supra-physiological toxicity unknown\", \"In vivo dosing window not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how GALC dosage mechanistically couples to broader pathways implicated by emerging models (microglial Trem2 regulation, amyloid processing, autophagy homeostasis) and which lipid species dominate human neuropathology.\",\n      \"evidence\": \"Open question synthesizing genetic dosage, lipidomic, and pathway findings\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No mechanistic link between GALC and amyloid processing established\", \"Causal lipid driver in human CNS not defined\", \"Pathway connection of GALC to senescence/cancer findings non-physiological\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0004553\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 0, 10, 11]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [1, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [0, 2, 4, 7]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 11, 4]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"complexes\": [\"GALC-SapA heterotetramer\"],\n    \"partners\": [\"PSAP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}